🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being viewed as a "huge turning point" in the fight against increasingly resistant strains of the bacteria, according to health experts.

An International Health Concern

Gonorrhoea infections are increasing globally, with estimates suggesting over 82 million infections per year. Notably increased rates are reported in Africa and nations within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have hit a record high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an significant and necessary advancement in the reality of growing infection rates, the spread of superbugs and the very limited available drugs currently available.”

Public health authorities are deeply concerned about the increase in treatment-resistant strains. The global health body has listed it as a "high-priority threat". Recent surveillance showed that the effectiveness of primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Therapies Receive Authorization

Zoliflodacin, also known as a brand name, was approved by the US FDA in recent days for use against gonorrhoea. This infection can lead to major issues, including the inability to conceive. Experts anticipate that targeted use of this new drug will help hinder the spread of drug resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, also received approval in close succession. This treatment, which is additionally indicated for UTIs, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

This new treatment emerged from a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to develop it.

“This approval marks a huge turning point in the treatment of multidrug-resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Testing Outcomes and Global Access

According to data published in a major medical journal, the new drug cured more than 90% of cases of the STI. This places it at an comparable level with the current standard treatment, which involves an injection and a pill. The study included nearly 1,000 patients from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, GARDP has the ability to make available and distribute the drug in many low-income and middle-income countries.

Clinicians on the front lines have shared optimism. The availability of a single-dose, oral treatment such as this is hailed as a "game-changer" for gonorrhoea control. This is viewed as essential to alleviate the strain of the disease for patients and to halt the transmission of untreatable gonorrhoea around the world.